The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.
Amir Goldkorn, MD
Advertisement
Articles by Amir Goldkorn, MD
Baseline CTC counts were shown to be strong indicators for subsequent therapy response and 2-year progression-free survival.
Advertisement
Latest Updated Articles
Amir Goldkorn, MD Talks Next Steps for SWOG 1216 TrialPublished: July 2nd 2020 | Updated:
Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPCPublished: May 30th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
